drugset / Trial / NCT01511848

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

NCT01511848

Phase 2/3 Unknown 60 enrolled Ain Shams University
RandomizedCrossoverOpen-labelTreatment

Summary

Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatment of transfusional iron overload Primary Outcome Measures: • The primary outcome measure is to assess efficacy in lowering serum ferritin level(the change in serum ferritin compared to baseline) with combining DFP and deferasirox compared to combined DFP and DFO in conditions with severe chronic iron overload; showing an up-trend of SF over previous 12 months on single chelator. Secondary Outcome Measures: • The secondary outcome measure is to determine the number of patients who will develop adverse events in order to assess safety upon administering the drugs in combination (DFP and DFX) compared to the combination of DFO and DFP.

Timeline

Start
2012-02
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Deferasirox Unknown 20 mg/kg Oral
Comparator Deferoxamine Other / unclassified 40 mg/kg Subcutaneous
Comparator Deferiprone Small molecule 75 mg/kg Oral
Comparator Deferiprone Small molecule 100 mg/kg Oral